CrisprBits, a Bengaluru-based biotechnology startup working at the intersection of CRISPR science and real-world diagnostics, has reached an important milestone with its latest funding achievement. The company has secured $3 million in a Pre-Series A round, bringing its overall valuation to $12 million.
The round was led by Spectrum Impact, the family office of Rajendra Gogri, who is the Chairman and Managing Director of Aarti Industries. Existing supporters such as the Vijay Alreja Family Office of VJ Technologies Group reaffirmed their confidence by participating again, while new backing also came from the promoter family of HBL Engineering.
This investment builds on earlier support from the founders themselves, VJ Technologies Group, and C-CAMP, helping the company strengthen its foundation in India’s growing deep-tech landscape.
Also Read: Lush Returns to India With Ambitious Plans in the Luxury Beauty Space
Expanding Diagnostics to Meet Real-World Needs
Most of the fresh money is oriented towards speeding up the commercial launch of PathCrisp, which is a molecular diagnostics platform based on CRISPR by CrisprBits. As these attributes are gaining more and more focus by the users of diagnostics – correctness, quickness, and accessibility – the enterprise is willing to implement the device in such fields where it is indispensable to have prompt yet trustworthy outcomes. Their expansion spans three major areas:
- Human health, where rapid disease detection can significantly improve patient outcomes
- Food safety, a sector where contamination monitoring is increasingly essential
- Animal health, where early diagnosis can reduce disease spread and economic losses
CrisprBits is increasing the scale of its manufacturing processes to be able to produce more tests while maintaining the same quality in order to help meet these objectives. The company is making a significant transition with this extension of its activities to less research-dependent and more commercially viable operations, thus enabling the enterprise to access broader markets.
Beyond diagnostics, the company is advancing a CRISPR-driven strain engineering platform, initially focused on enhancing biofuel production processes. This direction supports the broader shift toward sustainable technologies and signals how CRISPR can contribute to cleaner, more efficient industrial systems.
A Team and Facility Built for Deep-Tech Innovation
CrisprBits was founded by Vijay Chandru, Sunil Arora, Rajeev Kohli, Bharat Jobanputra, and Aditya Sarda, whose collective knowledge covers engineering, computation, life sciences, and product development. Their application of different fields of knowledge has not only made the company a leader in science but also a tech company with a firm engineering background.
The company operates from a 7,300-square-foot R&D and prototype development facility in Bengaluru. This space supports the development and refinement of next-generation CRISPR systems, enabling the team to build, test, and optimise tools across multiple applications.
CrisprBits’ work is organised into three interconnected platforms:
- PathCrisp, which drives the company’s molecular diagnostics initiatives
- EdiCrisp, focusing on gene editing and strain engineering
- CurieCrisp, targeting therapeutic development with an emphasis on preclinical and rare-disease solutions
These platforms allow the company to explore different dimensions of CRISPR technology while maintaining a unified mission: to create practical, reliable, scalable biotechnology for everyday use.
Taking Indian Biotech Solutions Beyond Borders
CrisprBits has set its sights on global outreach. Over the next six months, the company plans to introduce its diagnostic products to regions such as Africa and Latin America, where affordable and rapid molecular testing has the potential to create meaningful impact.
To prepare for this expansion, the company is strengthening manufacturing infrastructure and scaling operational capabilities at its diagnostics facility. Parallel efforts are underway to advance an AI-augmented strain-engineering platform, which will support sustainability-focused industrial applications.
A Step Forward for India’s CRISPR Journey
CrisprBits’ latest funding round is more than a financial boost, it reflects rising confidence in India’s presence within the global biotech sector. With work spanning human health, food systems, animal safety, and industrial sustainability, the company is positioning itself as a meaningful contributor to the future of CRISPR-enabled innovation.
While industries globally are going to precision diagnostics and eco-friendly technologies, a company such as CrisprBits is leading the way of the next generation of Indian deep-tech innovators who are set to create a global impact.
Also Read: AI Startup Greenshoe Raises $3 Million to Simplify SEC Disclosure Workflows
